Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Feb 15, 2020; 12(2): 124-148
Published online Feb 15, 2020. doi: 10.4251/wjgo.v12.i2.124
Published online Feb 15, 2020. doi: 10.4251/wjgo.v12.i2.124
Study setting | Sample type | Marker type | Biomarker(s) and detection methods | Sensitivity (or its range) | Specificity (or its range) | Ref. |
Case-control | Stool | MicroRNA | miR-18a, upregulated | 61.00% | 69.00% | [73] |
Case-control | Stool | MicroRNA | miR-20a, upregulated | 55.00% | 82.00% | [73] |
Case-control | Stool | MicroRNA | miR-21, upregulated | 56.0%-86.0% | 73.0%-81.1% | [73,74] |
Case-control | Stool | MicroRNA | miR-92a, upregulated | 72.00% | 73.00% | [73] |
Case-control | Stool | MicroRNA | miR-106a, upregulated | 34.00% | 97.00% | [73] |
Case-control | Stool | MicroRNA | miR-135b, upregulated | 78.00% | 68.00% | [73] |
Case-control | Stool | MicroRNA | miR-144*, upregulated | 74.00% | 87.00% | [73] |
Case-control | Stool | MicroRNA | miR-221, upregulated | 62.00% | 74.00% | [73] |
Case-control | Stool | MicroRNA | miR-223, upregulated | 77.00% | 96.00% | [75] |
Case-control | Stool | MicroRNA | miR-451, upregulated | 88.00% | 100.00% | [75] |
Case-control | Stool | MicroRNA panel | miR-223 and mir-92a, both upregulated | 97.00% | 75.00% | [73] |
Case-control | Stool | MicroRNA panel | miR-17-93 cluster and miR-135b, all upregulated | 74.00% | 79.00% | [73] |
Case-control | Stool | MicroRNA panel | miR-144-5p, miR-451a and miR-20b-5p, all upregulated | 66.00% | 95.00% | [76] |
Case-control | Plasma | MicroRNA | miR-17-3p, upregulated | 64.00% | 70.00% | [73,77] |
Case-control | Plasma | MicroRNA | miR-18a, upregulated | 73.10% | 79.10% | [77] |
Case-control | Plasma | MicroRNA | miR-20a, upregulated | 46.00% | 73.40% | [73,77] |
Case-control | Serum/plasma | MicroRNA | miR-21, upregulated | 65.0%-91.4% | 74.4%-95.0% | [73,77-79] |
Case-control | Plasma | MicroRNA | miR-24, downregulated | 78.40% | 83.80% | [77] |
Case-control | Plasma | MicroRNA | miR-29a, upregulated | 69.00% | 89.10% | [77] |
Case-control | Serum/plasma | MicroRNA | miR-29b, downregulated | 61.4%-77.0% | 72.5%-75.0% | [77] |
Case-control | Plasma | MicroRNA | miR-92, upregulated | 89.00% | 70.00% | [77] |
Case-control | Serum/plasma | MicroRNA | miR-92a, upregulated | 65.5%-84.0% | 71.2%-82.5% | [73,77] |
Case-control | Plasma | MicroRNA | miR-96, upregulated | 65.40% | 73.30% | [73,77] |
Case-control | Plasma | MicroRNA | miR-106a, upregulated | 74.00% | 44.40% | [77] |
Case-control | Serum | MicroRNA | miR-139-3p, downregulated | 96.60% | 97.80% | [80] |
Case-control | Serum | MicroRNA | miR-139a-5p, upregulated | 76.70% | 88.00% | [81] |
Case-control | Plasma | MicroRNA | miR-155, upregulated | 58.20% | 95.00% | [73] |
Case-control | Plasma | MicroRNA | miR-182, upregulated | 78.00% | 91.00% | [82] |
Case-control | Serum | MicroRNA | miR-194, downregulated | 72.00% | 80.00% | [77] |
Case-control | Serum | MicroRNA | miR-196b, upregulated | 63.00% | 87.40% | [84] |
Case-control | Plasma | MicroRNA | miR-200c, upregulated | 64.10% | 73.30% | [77] |
Case-control | Serum | MicroRNA | miR-210, upregulated | 74.6%-88.6% | 73.5%-90.1% | [77,79] |
Case-control | Plasma | MicroRNA | miR-221, upregulated | 86.00% | 41.00% | [73,77] |
Case-control | Plasma | MicroRNA | miR-320a, downregulated | 92.80% | 73.10% | [77] |
Case-control | Serum | MicroRNA | miR-338-5p, upregulated | 76.30% | 92.50% | [84] |
Case-control | Serum | MicroRNA | miR-372, upregulated | 81.90% | 73.30% | [77] |
Case-control | Serum | MicroRNA | miR-375, downregulated | 76.90% | 64.60% | [77] |
Case-control | Plasma | MicroRNA | miR-423-5p, downregulated | 91.90% | 70.80% | [77] |
Case-control | Plasma | MicroRNA | miR-506, upregulated | 76.80% | 60.70% | [85] |
Case-control | Plasma | MicroRNA | miR-601, downregulated | 69.20% | 72.40% | [77] |
Case-control | Plasma | MicroRNA | miR-760, downregulated | 80.00% | 72.40% | [77] |
Case-control | Serum | MicroRNA | miR-1290, upregulated | 70.10% | 91.20% | [86] |
Case-control | Plasma | MicroRNA | miR-4316, upregulated | 76.80% | 75.00% | [85] |
Case-control | Plasma | MicroRNA panel | miR-19a and miR-19b, both upregulated | 78.60% | 77.40% | [77] |
Case-control | Serum | MicroRNA panel | miR-21 and miR-92a, both upregulated | 68.00% | 91.20% | [73,77] |
Case-control | Plasma | MicroRNA panel | miR-29a and miR-92a, both upregulated | 83.00% | 84.70% | [73,77] |
Case-control | Plasma | MicroRNA panel | miR-200c and miR-18a, both upregulated | 84.60% | 75.60% | [36,77] |
Case-control | Plasma | MicroRNA panel | miR-223 and miR-92a, both upregulated | 76.00% | 71.00% | [73] |
Case-control | Plasma | MicroRNA panel | miR-320d, downregulated; miR-1290, upregulated | 81.20% | 90.70% | [87] |
Case-control | Plasma | MicroRNA panel | miR-431 and miR-139-p3, both upregulated | 91.00% | 57.00% | [77] |
Case-control | Plasma | MicroRNA panel | miR-601 and miR-760, both downregulated | 83.30% | 69.10% | [73,77] |
Case-control | Plasma | MicroRNA panel | miR-19a, miR-19b and miR-15b, all upregulated | 78.60% | 79.20% | [77] |
Case-control | Plasma | MicroRNA panel | miR-24, miR-320a and miR-423-5p, all downregulated | 92.80% | 70.80% | [36,77] |
Case-control | Plasma | MicroRNA panel | miR-144-3p, miR-425-5p and miR-1260b, all downregulated | 93.80% | 91.30% | [88] |
Case-control | Serum | MicroRNA panel | miR-145, downregulated; miR-106a and miR-17-3p, upregulated | 78.50% | 82.80% | [73,77] |
Case-control | Plasma | MicroRNA panel | miR-409-3p, upregulated; miR-7 and miR-93, downregulated | 82.00% | 89.00% | [73,77] |
Case-control | Plasma | MicroRNA panel | miR-18a, miR-21, miR-22 and miR-25, all upregulated | 67.00% | 90.00% | [89] |
Case-control | Serum | MicroRNA panel | miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p, all upregulated | 89.00% | 81% | [36] |
Case-control | Plasma | MicroRNA panel | miR-29a, miR-92a, upregulated; miR-601, miR-760, downregulated | 83.30% | 93.10% | [77] |
Case-control | Serum | MicroRNA panel | miR-21, miR-29, miR-92, miR-125, miR-223, all upregulated | 84.70% | 98.70% | [78] |
Case-control | Plasma | MicroRNA panel | miR-19a, miR-19b, miR-15b, miR-29a, miR-335, miR-18a, all upregulated | 91.00% | 90.00% | [90] |
Case-control | Plasma | MicroRNA panel | miR-21, let-7g, upregulated, mir-31, mir-92a, miR-181b, miR-203, downregulated | 96.00% | 81.00% | [73] |
Case-control | Plasma | MicroRNA panel | miR-103a-3p, miR-127-3p, miR-151a-5p, miR-17-5p, miR-181a-3p, miR-18a-5p, miR-18b-5p, all upregulated | 76.90% | 86.70% | [91] |
Case-control | Plasma | Exosomal MicroRNA panel | miR-27a, miR-130a, both upregulated | 82.50% | 75.00% | [92] |
Case-control | Saliva | MicroRNA | miR-21, upregulated | 97.00% | 91.00% | [93] |
- Citation: Loktionov A. Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins? World J Gastrointest Oncol 2020; 12(2): 124-148
- URL: https://www.wjgnet.com/1948-5204/full/v12/i2/124.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i2.124